Abstract:Introduction: All cosmetic ingredients must be evaluated for their safety to consumers. In the absence of in vivo data, systemic concentrations of ingredients can be predicted using Physiologically based Pharmacokinetic (PBPK) models. However, more examples are needed to demonstrate how they can be validated and applied in Next-Generation Risk Assessments (NGRA) of cosmetic ingredients. We used a bottom-up approach to develop human PBPK models for genistein and daidzein for a read-across NGRA, whereby genistein was the source chemical for the target chemical, daidzein. Methods: An oral rat PBPK model for genistein was built using PK-Sim® and in vitro ADME input data. This formed the basis of the daidzein oral rat PBPK model, for which chemical-specific input parameters were used. Rat PBPK models were then converted to human models using human-specific physiological parameters and human in vitro ADME data. In vitro skin metabolism and penetration data were used to build the dermal module to represent the major route of exposure to cosmetics. Results: The initial oral rat model for genistein was qualified since it predicted values within 2-fold of measured in vivo PK values. This was used to predict plasma concentrations from the in vivo NOAEL for genistein to set test concentrations in bioassays. Intrinsic hepatic clearance and unbound fractions in plasma were identified as sensitive parameters impacting the predicted Cmax values. Sensitivity and uncertainty analyses indicated the developed PBPK models had a moderate level of confidence. An important aspect of the development of the dermal module was the implementation of first-pass metabolism, which was extensive for both chemicals. The final human PBPK model for daidzein was used to convert the in vitro PoD of 33 nM (from an estrogen receptor transactivation assay) to an external dose of 0.2% in a body lotion formulation. Conclusion: PBPK models for genistein and daidzein were developed as a central component of an NGRA read-across case study. This will help to gain regulatory confidence in the use of PBPK models, especially for cosmetic ingredients.

Predicting points of departure and potency categories for fragrance ingredients by integrating OECD in vitro models

GARDskin dose-response assay and its application in conducting Quantitative Risk Assessment (QRA) for fragrance materials using a Next Generation Risk Assessment (NGRA) framework

Deriving a Continuous Point of Departure for Skin Sensitization Risk Assessment Using a Bayesian Network Model

Deriving a Point of Departure for Assessing the Skin Sensitization Risk of Wearable Device Constituents with In Vitro Methods

In Vitro Prediction of Skin-Sensitizing Potency Using the GARDskin Dose–Response Assay: A Simple Regression Approach

Integrated skin sensitization assessment based on OECD methods (II): Hazard and potency by combining kinetic peptide reactivity and the "2 out of 3" Defined Approach

Quantum-Mechanics Calculations Elucidate Skin-Sensitizing Pharmaceutical Compounds

Prediction of skin sensitization using machine learning

Potency classification of isothiazolinone compounds based on defined approaches of skin sensitization in OECD GL 497

An epidermal equivalent assay for identification and ranking potency of contact sensitizers

How to resolve inconclusive predictions from defined approaches for skin sensitisation in OECD Guideline No. 497

Integration of the Natural Language Processing of Structural Information Simplified Molecular-Input Line-Entry System Can Improve the In Vitro Prediction of Human Skin Sensitizers

In Vitro Dendritic Cell-Based Test for Skin Sensitizers Identification and Potency Estimation

Development of Validated Quantitative Structure-Retention Relationship Models for Retention Indices of Plant Essential Oils

Development of an in silico evaluation system that quantitatively predicts skin sensitization using OECD Guideline No. 497 ITSv2 defined approach for skin sensitization classification

Increasing Accessibility of Bayesian Network-Based Defined Approaches for Skin Sensitisation Potency Assessment

Improved Defined Approaches for Predicting Skin Sensitization Hazard and Potency in Humans

Skin Sensitization Potency Prediction Based on Read‐Across (RAx) Incorporating RhE‐Based Testing Strategy (RTSv1)–Defined Approach: RTSv1‐Based RAx

Chemometric model for predicting retention indices of constituents of essential oils

Prediction of the Skin Sensitising Potential and Potency of Compounds Via Mechanism-Based Binary and Ternary Classification Models.

Development and validation of PBPK models for genistein and daidzein for use in a next-generation risk assessment